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Reply to Dr O’Driscoll 
In Denmark and a number of other European 
countries, anti-cholinergic dry powder therapy is 
available. Ipratropium is inhaled by the Inhalator 
Ingelheim, either alone (Atrovent capsules, 40 mg) or 
as a fixed combination (Berodual capsules with 40 mg 
ipratropium + 100 mg fenoterol). For patients with 
severe COPD, I usually recommend ipratropium dry 
powder 4&80 mg four times per day in combination 
with a short acting &stimulator (as dry powder) 
taken as needed. We seldom prescribe a nebulizer 
anymore, and during the last 5 yr the number of 
adult nebulizer users in the local area has decreased 
from about 330 to less than 220. 
Astra Draco AB, Sweden has kindly supplied data 
for countries where terbutaline (Bricanyl) is available 
both as Turbuhaler and as respules, and I have 
calculated the following ratios between the prices of 
2.5 mg terbutaline from Turbuhaler (=five doses) 
and 5 mg terbutaline nebulizer solution (= 1 respule): 
Denmark: 0.37, Sweden: 0.75, Norway: 0.80, Iceland: 
0.81, Australia: 1.01, Switzerland: 1.14, U.K.: 2.846. 
The great difference between Denmark and U.K. 
prices is mainly due to a much lower price of 
nebulizer solution in the U.K. 
N. C. G. HANSEN 
Department of Respiratory Diseases (C) 
Odense University Hospital 
DK-5000 Odense C, Denmark 
Dear Editor 
Flumazenil to reverse midazolam sedation 
Williams et al. (1) report the use of high dose 
intravenous midazolam for sedation during fibreoptic 
bronchoscopy. Although the mean dose used of 
0.24 f 0.1 mg kg - ’ is within the recommended range 
for the induction of anaesthesia, some patients 
received over twice this dose, with the upper range 
being 0.67 mg kg - ’ . 9.8% of the total 123 patients 
were given intravenous flumazenil to reverse the 
effects of midazolam because there were insufficient 
nursing staff available to look after recovery patients. 
This is of concern, firstly because the side-effects of 
flumazenil are nausea, vomiting, agitation, flushing, 
anxiety and fear: the very sensations this technique is 
trying to avoid. Secondly, flumazenil is very short- 
acting, and when high doses of midazolam are used, 
with an average half-life of 2 h, repeated doses of 
flumazenil may have to be given. Therefore it would 
seem that nursing or medical staff would need to 
observe closely these patients after bronchoscopy, 
rather than using this as a method of reducing the 
need for observation. 
F. M. HARDINGE 
Osler Chest Unit 
Churchill Hospital 
Headington 
Oxford, U.K. 
28 June 1994 
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Reply to Dr Hardinge 
Dr Hardinge makes two valid points about the use 
of intravenous flumazenil to reverse the effects of 
midazolam sedation. 
We did not specifically ask patients about possible 
side effects after using flumazenil, but judged from 
our questionnaire those patients who did not fmd the 
procedure any more unpleasant than patients not 
given flumazenil 
Certainly, flumazenil has a shorter half life than 
midazolam, but in practice this did not seem to be a 
problem and no patient needed repeated doses of 
flumazenil. 
However, we are now fortunate in having the 
use of a fully staffed Day Case Unit so only use 
flumazenil when worried about a patient’s condition, 
e.g. when there is a lot of bleeding. 
I was very grateful to Dr Hardinge for raising these 
points. 
T. J. WILLIAMS 
Kettering General Hospital NHS Trust 
Rothwell Road 
Kettering 
Northamptonshire NN16 8UZ U.K. 
